Interestingly, RRAGD deep deletion in prostate adenocarcinoma strongly correlates with FOXO3 deletion (one-sided Fisher’s Exact test, p-value < 0.001; data sourced from the cBioPortal platform, TCGA Firehose Legacy prostate adenocarcinoma dataset, n = 492), however the functional consequence of RRAGD/FOXO3 co-deletion and RAGB amplification during prostate cancer growth and therapeutic resistance is currently unknown and merits further investigation. The gene discussed is FOXO3; the disease is prostate adenocarcinoma.